Jae Park, MD
Memorial Sloan Kettering Cancer Center
Emerging Leaders
not ranked
Current Leaders
#4142 pts
All-Time Leaders
#61824 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2007. 14 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase I Study of ADCLEC.syn1 CAR T Cells in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1RecruitingMemorial Sloan Kettering Cancer Center
8
impact
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Phase 1ActiveMemorial Sloan Kettering Cancer Center
5
impact
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Phase 1RecruitingMemorial Sloan Kettering Cancer Center
3
impact
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
Phase 1ActiveMemorial Sloan Kettering Cancer Center
2
impact
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Phase 2ActiveMemorial Sloan Kettering Cancer Center
2
impact
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Phase 2ActiveMemorial Sloan Kettering Cancer Center
1
impact
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Phase 2ActiveMemorial Sloan Kettering Cancer Center
1
impact
A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells
Phase 2ActiveMemorial Sloan Kettering Cancer Center
0
impact
A Phase 1/2 Study of Concurrent Inotuzumab and Subcutaneous Blinatumomab in Adult Patients With B-cell Acute Lymphoblastic Leukemia
Phase 2Not Yet RecruitingMemorial Sloan Kettering Cancer Center
0
impact
A Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab in Patients With Previously Untreated Hairy Cell Leukemia (HCL)
Phase 2RecruitingMemorial Sloan Kettering Cancer Center
0
impact
A Phase I Study of T-cell Receptor Alpha Constant (TRAC) Locus Integrated CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With CD19+ Relapsed or Refractory Large B-Cell Lymphoma
Phase 1ActiveMemorial Sloan Kettering Cancer Center
0
impact
Venetoclax in Combination With Asparaginase-Containing Pediatric-Inspired Chemotherapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Early Ph 1ActiveMemorial Sloan Kettering Cancer Center
0
impact
A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL "Armored" Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1ActiveMemorial Sloan Kettering Cancer Center
0
impact
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Phase 1WithdrawnMemorial Sloan Kettering Cancer Center
0
impact
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.
Phase 1ActiveMemorial Sloan Kettering Cancer Center
0
impact
A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Phase 1CompletedMemorial Sloan Kettering Cancer Center
0
impact
Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2CompletedMemorial Sloan Kettering Cancer Center
0
impact